Baseimmune develops vaccines that protect against current infectious diseases and future evolving variants. The company’s goal is to defend populations against future pandemics and emerging health threats.
Viruses often mutate rapidly, reducing the efficacy of existing vaccines over time. Baseimmune’s AI engine accurately models pathogen evolution to predict future mutations. This enables the creation of vaccines that are longer-lasting with broader coverage. Baseimmune currently has four in-house vaccine programs in the pre-clinical phase of development.
The company was founded by Joshua Blight (CEO) and Ariane Gomes (CSO) in 2019 who pioneered the use of computational approaches to design vaccines against infectious diseases while at the University of Oxford's Jenner Institute.
